THE DUBERSTEIN GROUP INC. for PHRMA INC.
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
GSP and IP protections.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Medicare/Medicaid MMM
Impact of fiscal deficit, including continuing resolution and debt limit extension on Medicare Part D and sustainable growth rate - HJRes 59 - Continuing Appropriations Resolution, 2014; HR 2810, Medicare Patient Access and Quality Improvement Act of 2013; proposed legislation re these issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
| DANIEL P MEYER | — |
Budget/Appropriations BUD
Impact of fiscal deficit issues, including debt limit extension and continuing resolution on healthcare - HJRes 59, Continuing Appropriations Resolution, 2014.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Pharmacy PHA
Pharmaceutical issues, including Track and Trace - HR 1919, Safeguarding America's Pharmaceuticals Act of 2013; HR 3204, Drug Quality and Security Act; S 957, Drug Supply Chain Security Act. Impact of sequestration on FDA user fees - Proposed legislation re this issue; Executive Branch action re this issue.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.